FY2028 Earnings Estimate for Invivyd Issued By HC Wainwright

Invivyd, Inc. (NASDAQ:IVVD) – Investment analysts at HC Wainwright lifted their FY2028 earnings per share (EPS) estimates for shares of Invivyd in a report issued on Monday, June 15th. HC Wainwright analyst P. Trucchio now expects that the company will earn $0.25 per share for the year, up from their prior forecast of $0.24. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Invivyd’s FY2029 earnings at $0.68 EPS and FY2030 earnings at $1.21 EPS.

Invivyd (NASDAQ:IVVD) last issued its earnings results on Thursday, May 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.05). The business had revenue of $13.74 million during the quarter, compared to analyst estimates of $18.04 million. Invivyd had a negative net margin of 138.90% and a negative return on equity of 53.48%.

Several other equities research analysts have also recently commented on IVVD. Weiss Ratings reissued a “sell (d-)” rating on shares of Invivyd in a research note on Wednesday, April 29th. Wall Street Zen cut Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, BTIG Research reissued a “buy” rating and issued a $10.00 price target on shares of Invivyd in a research note on Tuesday, June 9th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $8.00.

Invivyd Stock Performance

Shares of NASDAQ IVVD opened at $0.87 on Tuesday. The stock has a market cap of $255.90 million, a price-to-earnings ratio of -2.80 and a beta of 0.63. The business has a 50 day simple moving average of $1.31 and a 200 day simple moving average of $1.76. Invivyd has a 52 week low of $0.48 and a 52 week high of $3.07.

Institutional Investors Weigh In On Invivyd

Large investors have recently made changes to their positions in the company. GSA Capital Partners LLP boosted its position in Invivyd by 85.0% during the third quarter. GSA Capital Partners LLP now owns 805,221 shares of the company’s stock worth $886,000 after purchasing an additional 369,891 shares during the period. Eventide Asset Management LLC bought a new stake in Invivyd during the fourth quarter worth approximately $14,349,000. UBS Group AG boosted its position in Invivyd by 683.8% during the fourth quarter. UBS Group AG now owns 1,050,923 shares of the company’s stock worth $2,596,000 after purchasing an additional 916,842 shares during the period. Eversept Partners LP boosted its position in Invivyd by 4.5% during the fourth quarter. Eversept Partners LP now owns 2,140,130 shares of the company’s stock worth $5,286,000 after purchasing an additional 92,865 shares during the period. Finally, BVF Inc. IL bought a new stake in shares of Invivyd in the fourth quarter valued at approximately $48,227,000. Institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.